Prostate Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Prostate cancer is the most common non-skin cancer in men globally, with approximately 1.4 million new cases and 375,000 deaths annually worldwide (2022). It is predominantly a disease of older men — over 60% of cases are diagnosed in men above 65 years — and displays a wide spectrum of biological behaviour, from indolent low-risk disease that may never require treatment to aggressive metastatic cancers that are rapidly fatal despite treatment.

The heterogeneity of prostate cancer behaviour is its defining clinical challenge. Screening with prostate-specific antigen (PSA) has dramatically shifted the stage at diagnosis toward earlier, localised disease, but has also generated significant overdiagnosis and overtreatment concerns. Modern risk stratification combines PSA level, Gleason grade (now expressed as International Society of Urological Pathology Grade Group 1–5), clinical T-stage, and multiparametric MRI (mpMRI) findings to categorise disease into very low, low, intermediate (favourable/unfavourable), high, and very high risk groups — each with different treatment recommendations.

Treatment options for localised prostate cancer include active surveillance (closely monitoring low-risk disease without immediate treatment), radical prostatectomy (surgical removal of the prostate), and radiotherapy (external beam or brachytherapy). All three achieve similar long-term cancer-specific survival for low-risk disease; the ProtecT trial (10-year follow-up) confirmed equivalent prostate cancer-specific mortality for active monitoring, surgery, and radiotherapy for clinically localised disease. For advanced and metastatic disease, androgen deprivation therapy (ADT) forms the backbone, increasingly combined with novel androgen receptor pathway inhibitors (enzalutamide, abiraterone, darolutamide), chemotherapy, PARP inhibitors (for BRCA-mutated disease), and PSMA-targeted radioligand therapy (lutetium-177-PSMA-617).

• Very low / low risk (Gleason 6, PSA <10, cT1-2a): Active surveillance is the preferred management for most very low-risk and low-risk prostate cancer in men with life expectancy >10 years. Active surveillance involves PSA every 6 months, annual digital rectal exam, repeat biopsy at 12–18 months, and mpMRI surveillance. Approximately 50% of monitored patients undergo curative treatment within 10 years (triggered by grade reclassification or patient preference). Cancer-specific mortality at 10–15 years is <1% on active surveillance for well-selected patients.
• Intermediate risk (Gleason 7 = Grade Group 2–3, PSA 10–20, or cT2b–c): Curative treatment recommended — radical prostatectomy with pelvic lymph node dissection (PLND) or external beam radiation therapy (EBRT) with short-course androgen deprivation therapy (ADT) 4–6 months for unfavourable intermediate risk. Both approaches achieve equivalent cancer control in RCTs. Treatment choice based on patient preference, comorbidities, urinary/sexual/bowel function, and quality-of-life priorities.
• High risk / locally advanced (Gleason 8–10 = GG 4–5, PSA >20, cT3-4 or N1): Radical prostatectomy with PLND (± adjuvant radiation for positive margins/nodes); or EBRT + long-term ADT (18–36 months). STAMPEDE trial: abiraterone + ADT + EBRT for high-risk localised disease reduces biochemical failure and metastatic progression. Multiparametric MRI staging and PSMA-PET CT increasingly used to detect regional and distant metastases before definitive local therapy.
• Biochemical recurrence after primary treatment: Rising PSA after prostatectomy (PSA >0.2 ng/mL) or after radiation (PSA nadir + 2 ng/mL). PSMA-PET CT (Gallium-68-PSMA) detects recurrence site in 75–80% of patients with PSA ≥0.5 ng/mL. Salvage radiation for post-prostatectomy PSA rise; salvage prostatectomy for post-radiation local recurrence at specialist centres; ADT for disseminated recurrence.
• Metastatic hormone-sensitive prostate cancer (mHSPC): ADT + docetaxel (CHAARTED/STAMPEDE trials) or ADT + abiraterone (LATITUDE) or ADT + enzalutamide/apalutamide/darolutamide (ARCHES/TITAN/ARASENS trials) — all significantly superior to ADT alone. Combination ADT + androgen receptor pathway inhibitor (ARPI) + docetaxel (triplet therapy: PEACE-1, ARASENS) achieves further OS benefit for high-volume metastatic disease.
• Metastatic castration-resistant prostate cancer (mCRPC): Disease progressing despite castrate testosterone (<50 ng/dL). Options: enzalutamide (PREVAIL trial: mOS 32 months vs. 30 months placebo), abiraterone (COU-AA-302), cabazitaxel (chemotherapy post-docetaxel), olaparib/rucaparib for BRCA1/2-mutated mCRPC (PROfound trial), lutetium-177-PSMA-617 (VISION trial: mOS 15 months vs. 11 months with best standard care in PSMA-positive mCRPC). Pembrolizumab for MSI-H/dMMR mCRPC.

Diagnostic workup:

• PSA measurement and digital rectal examination (DRE)
• Multiparametric MRI (mpMRI) prostate — PI-RADS 3–5 lesions biopsied; PI-RADS 1–2 with PSA density <0.15 may be managed with surveillance without immediate biopsy
• Targeted and systematic biopsy — transperineal preferred over transrectal (lower sepsis risk). Minimum 12 cores systematic biopsy + targeted cores to PI-RADS 3–5 lesions
• Staging: PSMA-PET CT (Gallium-68 or Fluorine-18 PSMA ligands) for unfavourable intermediate, high-risk, or biochemically recurrent disease — superior to conventional imaging for detecting metastases at low PSA levels

Active surveillance eligibility (EAU guidelines 2025):

• Very low risk: clinical T1c–T2a, PSA ≤10, Gleason 6 (GG1), ≤50% positive cores, PSA density <0.15
• Low risk: cT1–T2a, PSA <10, Gleason 6
• Selected favourable intermediate risk (GG2): carefully considered active surveillance in well-informed patients who understand higher disease progression risk

Surgical eligibility for radical prostatectomy:

• Life expectancy >10 years; no major contraindications to surgery; no evidence of distant metastases
• Nerve-sparing prostatectomy considered for: potent patients, organ-confined disease on mpMRI, PSA <10, GG1–2 — to preserve erectile function (bilateral nerve-sparing: 40–60% erection recovery at 12 months at high-volume centres)

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

• Excellent survival for localised disease: 5-year relative survival for localised prostate cancer exceeds 99% regardless of primary treatment modality. The ProtecT trial demonstrated equivalent prostate cancer-specific mortality at 10 years for active monitoring, radical prostatectomy, and radiotherapy in clinically localised disease — validating patient-centred treatment choice.
• Robotic prostatectomy advantages: Robot-assisted radical prostatectomy (RARP) has become the dominant surgical approach globally (~85% of prostatectomies in the USA are robotic). Advantages over open prostatectomy: blood transfusion rate <1% (vs. 5–20% open), hospital stay 1–2 days (vs. 3–7 days), return to continence 6–8 weeks (vs. 8–12 weeks), similar oncological outcomes (positive margin rate, PSA recurrence-free survival).
• Novel hormonal agents for metastatic disease: Enzalutamide, abiraterone, apalutamide, and darolutamide added to standard ADT for metastatic hormone-sensitive disease significantly extend overall survival — TITAN trial (apalutamide + ADT): 4-year OS 66% vs. 52% with ADT alone. These oral agents allow patients to maintain functional independence with manageable side effects.
• PSMA-targeted therapy: Lutetium-177-PSMA-617 (Pluvicto) is a radioligand therapy that delivers targeted radiation to PSMA-expressing prostate cancer cells, approved for mCRPC post-ARPI and taxane chemotherapy. VISION trial: mOS 15 months vs. 11 months; rPFS 8.7 vs. 3.4 months. A paradigm shift in targetable metastatic prostate cancer.
• PARP inhibitors for BRCA-mutated disease: Approximately 12–15% of mCRPC patients harbour BRCA1/2 mutations. Olaparib achieves ORR 33% (vs. 2% with enzalutamide/abiraterone) and mPFS 7 months (vs. 3.6 months) for BRCA-mutated mCRPC post-ARPI (PROfound trial). Germline BRCA testing is now recommended for all metastatic prostate cancer patients.

• Urinary incontinence (post-prostatectomy): The most impactful quality-of-life complication. At 12 months: 15–25% of men require ≥1 pad per day (stress incontinence from external urethral sphincter damage). Pelvic floor physiotherapy significantly accelerates recovery. Severe persistent incontinence (5–10%) may require artificial urinary sphincter or urethral sling procedures.
• Erectile dysfunction (post-prostatectomy): Neurovascular bundle injury is universal in non-nerve-sparing surgery. With bilateral nerve-sparing RARP: erectile function recovery rates of 40–70% at 12–24 months depending on baseline function and nerve preservation quality. Penile rehabilitation (PDE5 inhibitors, vacuum erection device) initiated immediately post-operatively improves long-term erectile function.
• Radiation late effects: Rectal bleeding (radiation proctitis): 3–5% grade 3+; urethral stricture: 5–10%; cystitis and urinary frequency: 20–30%; bowel urgency: 10–20%; erectile dysfunction: 30–50% at 5 years (cumulative). Proton therapy and SBRT (5 fractions stereotactic prostate radiotherapy — PACE-B trial) show similar toxicity to IMRT with potential for superior OAR (organs at risk) sparing.
• Hormone therapy side effects: Androgen deprivation therapy (GnRH agonists/antagonists): hot flushes (80%), loss of libido, erectile dysfunction, muscle loss and sarcopenia, bone loss/osteoporosis (bisphosphonate/denosumab prophylaxis required), metabolic syndrome, depression, cognitive effects, and cardiovascular disease. Enzalutamide: fatigue (50%), falls and fractures, cognitive effects, hypertension, rarely seizures (<1%). Abiraterone: fluid retention, hypertension, hypokalaemia, hepatotoxicity (ALT monitoring required).
• Biochemical recurrence: After radical prostatectomy for intermediate-high risk disease: 20–30% develop PSA recurrence within 5 years despite curative-intent surgery. Salvage radiotherapy for post-prostatectomy PSA rise achieves biochemical control in 70% if initiated early (PSA <0.5 ng/mL). After radiotherapy: PSA bounce (transient rise without disease recurrence) occurs in 15–30% of brachytherapy patients, causing diagnostic confusion.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Prostate cancer treatment costs vary dramatically internationally. Robotic prostatectomy, novel hormonal agents, and PSMA therapy are expensive in Western countries but significantly more affordable in India and other medical tourism destinations:

• India: Robotic prostatectomy (da Vinci system): USD 3,500–8,000 at accredited hospitals — 80–90% less than US costs. Radiation therapy (IMRT, 25–28 fractions): USD 2,000–6,000. Brachytherapy: USD 4,000–8,000. Enzalutamide (Xtandi): USD 500–800/month in India (generic available) vs. USD 12,000–18,000/month in USA. Abiraterone: USD 200–400/month (Indian generic) vs. USD 9,000–15,000/month in USA. Active surveillance monitoring: USD 200–400/year for PSA + MRI in India. Da Vinci robotic prostatectomy available at Apollo, Fortis, Manipal, and Tata hospitals across India.
• Thailand: Robotic prostatectomy USD 8,000–15,000. Novel hormonal agents at approximately 20–30% of US costs.
• Turkey: Robotic prostatectomy USD 6,000–12,000. Strong urology infrastructure.
• Germany: Open or robotic prostatectomy EUR 15,000–25,000. Proton therapy for prostate: EUR 25,000–40,000 at specialist centres (Heidelberg, Munich).
• United States: Robotic prostatectomy USD 20,000–50,000 (all-in); radiation therapy (IMRT/SBRT): USD 25,000–50,000; enzalutamide: USD 12,000–18,000/month; abiraterone: USD 9,000–15,000/month; lutetium-177-PSMA: USD 42,000 per cycle (6 cycles = ~USD 250,000).
• United Kingdom (NHS): Radical prostatectomy and radiotherapy free for eligible patients. Robot-assisted prostatectomy widely available on NHS. Novel agents (enzalutamide, abiraterone, apalutamide, olaparib, Lu-177-PSMA) funded on NHS through NICE or Cancer Drugs Fund approval. Private sector: GBP 10,000–20,000 for robotic prostatectomy.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.